UroGen Pharma Ltd.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $180.3M | $49.7M |
| FY2020 | — | $96.4M | $52.9M |
| FY2021 | $0 | $8.4M | $44.4M |
| FY2022 | $97.5M | $-89.4M | $55.4M |
| FY2023 | $98.6M | $-65.2M | $95.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $180.3M | $49.7M |
| FY2020 | — | $96.4M | $52.9M |
| FY2021 | $0 | $8.4M | $44.4M |
| FY2022 | $97.5M | $-89.4M | $55.4M |
| FY2023 | $98.6M | $-65.2M | $95.0M |